Related Experiment Video

Updated: Jul 13, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

Small molecule and novel treatments for chronic hepatitis C virus infection

Stephen A Harrison1

  • 1Brooke Army Medical Center, Division of Gastroenterology and Hepatology, Department of Medicine, Fort Sam Houston, Texas, USA.

The American Journal of Gastroenterology
|July 10, 2007
PubMed

Insights

New molecular therapies show promise for chronic hepatitis C virus (HCV) infection, offering alternatives to current treatments. Research is ongoing to optimize these novel agents for improved efficacy and tolerability.

Area of Science:

  • Hepatology and Virology
  • Infectious Diseases
  • Pharmacology

Background:

  • Chronic hepatitis C virus (HCV) infection lacks effective treatments for nonresponders to standard therapy.
  • Current standard of care, pegylated interferon alfa (PEG-IFNalpha) and ribavirin (RBV), has limited efficacy and tolerability.
  • Development of alternative therapies is crucial for patients with HCV nonresponse or relapse.

Purpose of the Study:

  • To review the development of novel molecular-based therapies for chronic HCV infection.
  • To evaluate the potential of Specifically Targeted Antiviral Therapy for HCV (STAT-C) agents.
  • To discuss emerging treatments including RBV prodrugs and albumin-modified IFNalpha.

Main Methods:

  • Review of preliminary clinical data for STAT-C agents.
  • Assessment of combination therapy efficacy with PEG-IFNalpha.
  • Evaluation of safety, tolerability, and resistance profiles of new agents.

Main Results:

  • STAT-C agents demonstrate high antiviral activity, particularly in combination therapy.
  • Some STAT-C agents are tolerable but have shown identified resistance mutations.
  • Novel therapies like RBV prodrugs and albumin-modified IFNalpha may improve outcomes and tolerability.

Conclusions:

  • Small molecule and novel therapies for HCV infection show promise in clinical trials.
  • Ongoing research aims to develop new agents and optimize treatment regimens for HCV.
  • Further studies are needed to clarify the safety, tolerability, and efficacy of these emerging treatments.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...